


## VEGFR-2-IN-13

Cat. No.:	HY-144754
CAS No.:	2839104-01-5
Molecular Formula:	C <sub>24</sub> H <sub>18</sub> N <sub>6</sub> O <sub>2</sub> S
Molecular Weight:	454.5
Target:	VEGFR; Apoptosis
Pathway:	Protein Tyrosine Kinase/RTK; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

Description	VEGFR-2-IN-13 (Compound 19a) is a potent VEGFR-2 inhibitor with an IC <sub>50</sub> of 3.4 nM. VEGFR-2-IN-13 disrupts the HepG2 cell cycle by arresting the G2/M phase and induces apoptosis <sup>[1]</sup> .
IC <sub>50</sub> & Target	VEGFR2 3.4 nM (IC <sub>50</sub> )
In Vitro	VEGFR-2-IN-13 (Compound 19a) shows anti-proliferative activities with IC <sub>50</sub> values of 8.2 μM and 5.4 μM against MCF-7 and HepG2 cells, respectively <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Alsaif NA, et al. Identification of new [1,2,4]triazolo[4,3-a]quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies. *Bioorg Med Chem*. 2021 Sep 15;46:116384.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA